9. Indivior (LON:INDV) Q1 19 – 02/05
Last month Indivior shares plunged over 70% after the company was indicted by a US Federal Jury for fraudulent misrepresentation with respect to its Suboxone Film opioid treatment. The shares have managed to stabilise somewhat in the aftermath of that news however the outlook still looks bleak.
This week’s Q1 trading could well add some extra colour to this story, however the survival of the firm still remains a risk if the charges lead to the maximum $3bn fine being levied. If this were its only problem there might be light at the end of the tunnel, however sales from its other products have been struggling, due to competition from more generic rivals
